Patents by Inventor Andrew Scribner

Andrew Scribner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11759462
    Abstract: The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.
    Type: Grant
    Filed: March 15, 2021
    Date of Patent: September 19, 2023
    Inventors: Stéphane De Lombaert, Daniel R. Goldberg, Kenneth Brameld, Eric Brian Sjogren, Andrew Scribner
  • Publication number: 20210205305
    Abstract: The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.
    Type: Application
    Filed: March 15, 2021
    Publication date: July 8, 2021
    Applicant: Altavant Sciences GmbH
    Inventors: Stéphane De Lombaert, Daniel R. Goldberg, Kenneth Brameld, Eric Brian Sjogren, Andrew Scribner
  • Patent number: 10946018
    Abstract: The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.
    Type: Grant
    Filed: April 16, 2020
    Date of Patent: March 16, 2021
    Assignee: Roivant Sciences GmbH
    Inventors: Stéphane De Lombaert, Daniel R. Goldberg, Kenneth Brameld, Eric Brian Sjogren, Andrew Scribner
  • Patent number: 10738084
    Abstract: The invention relates to cyclic compounds of general formula (I): wherein R1, R2 and R3 are as defined in the specification, and their use as pharmaceuticals.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: August 11, 2020
    Assignee: Sentry Therapeutics Limited
    Inventors: Michael Peel, Andrew Scribner, Koichi Watashi, Satomi Shimura
  • Publication number: 20200237760
    Abstract: The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.
    Type: Application
    Filed: April 16, 2020
    Publication date: July 30, 2020
    Applicant: Roivant Sciences GmbH
    Inventors: Stéphane De Lombaert, Daniel R. Goldberg, Kenneth Brameld, Eric Brian Sjogren, Andrew Scribner
  • Patent number: 10660893
    Abstract: The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.
    Type: Grant
    Filed: May 30, 2019
    Date of Patent: May 26, 2020
    Assignee: ROIVANT SCIENCES, GmbH
    Inventors: Stéphane De Lombaert, Daniel R. Goldberg, Kenneth Brameld, Eric Brian Sjogren, Andrew Scribner
  • Publication number: 20190282575
    Abstract: The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.
    Type: Application
    Filed: May 30, 2019
    Publication date: September 19, 2019
    Applicant: Altavant Sciences GmbH
    Inventors: Stéphane De Lombaert, Daniel R. Goldberg, Kenneth Brameld, Eric Brian Sjogren, Andrew Scribner
  • Patent number: 10350208
    Abstract: The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: July 16, 2019
    Assignee: Roivant Sciences GmbH
    Inventors: Stéphane De Lombaert, Daniel R. Goldberg, Kenneth Brameld, Eric Brian Sjogren, Andrew Scribner
  • Publication number: 20180256574
    Abstract: The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.
    Type: Application
    Filed: May 14, 2018
    Publication date: September 13, 2018
    Inventors: Stéphane De Lombaert, Daniel R. Goldberg, Kenneth Brameld, Eric Brian Sjogren, Andrew Scribner
  • Patent number: 10045988
    Abstract: The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: August 14, 2018
    Assignee: Roivant Sciences GmbH
    Inventors: Stéphane De Lombaert, Daniel R. Goldberg, Kenneth Brameld, Eric Brian Sjogren, Andrew Scribner
  • Publication number: 20180186836
    Abstract: The invention relates to cyclic compounds of general formula (I): wherein R1, R2 and R3 are as defined in the specification, and their use as pharmaceuticals.
    Type: Application
    Filed: June 30, 2016
    Publication date: July 5, 2018
    Applicant: Cypra;os Limited
    Inventors: Michael Peel, Andrew Scribner, Koichi Watashi, Satomi Shimura
  • Publication number: 20180092918
    Abstract: The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.
    Type: Application
    Filed: July 10, 2017
    Publication date: April 5, 2018
    Inventors: Stéphane De Lombaert, Daniel R. Goldberg, Kenneth Brameld, Eric Brian Sjogren, Andrew Scribner
  • Publication number: 20180066523
    Abstract: An airfoil cooling system (54) for a gas turbine engine (10) is disclosed. The airfoil cooling system (54) may be formed from at least a first cooling fluid supply system (56), and a second cooling fluid supply system (58). The first cooling fluid supply system (56) may be configured to supply cooling fluids at a first pressure to one or more airfoils of a first row (68) of airfoils, and the second cooling fluid supply system (58) may be configured to supply cooling fluids at a second pressure to the one or more airfoils of the first row (68) of airfoils. Additionally, the second pressure may be lower than the first pressure. As such, each of the one or more airfoils may be cooled by cooling fluids at two different pressures. In particular embodiments, this may allow the airfoils to be cooled, while lowering the cost to the turbine engine (10) for providing such cooling.
    Type: Application
    Filed: April 6, 2015
    Publication date: March 8, 2018
    Inventors: Jan H. Marsh, John J. Marra, Carmen Andrew Scribner
  • Patent number: 9797259
    Abstract: A turbine airfoil cooling system including a low pressure cooling system and a high pressure cooling system for a turbine airfoil of a gas turbine engine is disclosed. In at least one embodiment, the low pressure cooling system may be an ambient air cooling system, and the high pressure cooling system may be a compressor bleed air cooling system. In at least one embodiment, the compressor bleed air cooling system in communication with a high pressure subsystem that may be a snubber cooling system positioned within a snubber. A delivery system including a movable air supply tube may be used to separate the low and high pressure cooling subsystems. The delivery system may enable high pressure cooling air to be passed to the snubber cooling system separate from low pressure cooling fluid supplied by the low pressure cooling system to other portions of the turbine airfoil cooling system.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: October 24, 2017
    Assignee: SIEMENS ENERGY, INC.
    Inventors: Jan H. Marsh, Stephen John Messmann, Carmen Andrew Scribner
  • Patent number: 9797267
    Abstract: A turbine airfoil assembly for installation in a gas turbine engine. The airfoil assembly includes an endwall and an airfoil extending radially outwardly from the endwall. The airfoil includes pressure and suction sidewalls defining chordally spaced apart leading and trailing edges of the airfoil. An airfoil mean line is defined located centrally between the pressure and suction sidewalls. An angle between the mean line and a line parallel to the engine axis at the leading and trailing edges defines gas flow entry angles, ?, and exit angles, ?. Airfoil inlet and exit angles are substantially in accordance with inlet angle values, ?, and exit angle values, ?, set forth in one of Tables 1, 2, 3, and 4.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: October 24, 2017
    Assignee: SIEMENS ENERGY, INC.
    Inventors: Andrew S. Lohaus, Anthony J. Malandra, Carmen Andrew Scribner, Farzad Taremi, Horia Flitan, Ching-Pang Lee, Gm Salam Azad, Tobias Buchal
  • Publication number: 20170095476
    Abstract: The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.
    Type: Application
    Filed: September 28, 2016
    Publication date: April 6, 2017
    Inventors: Stéphane De Lombaert, Daniel R. Goldberg, Kenneth Brameld, Eric Brian Sjogren, Andrew Scribner
  • Patent number: 9512122
    Abstract: The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.
    Type: Grant
    Filed: September 1, 2015
    Date of Patent: December 6, 2016
    Assignee: Karos Pharmaceuticals, Inc.
    Inventors: Stéphane De Lombaert, Daniel R. Goldberg, Kenneth Brameld, Eric Brian Sjogren, Andrew Scribner
  • Patent number: 9435212
    Abstract: A turbine airfoil usable in a turbine engine and having at least one snubber with a snubber cooling system positioned therein and in communication with an airfoil cooling system is disclosed. The snubber may extend from the outer housing of the airfoil toward an adjacent turbine airfoil positioned within a row of airfoils. The snubber cooling system may include an inner cooling channel separated from an outer cooling channel by an inner wall. The inner wall may include a plurality of impingement cooling orifices that direct impingement fluid against an outer wall defining the outer cooling channel. In one embodiment, the cooling fluids may be exhausted from the snubber, and in another embodiment, the cooling fluids may be returned to the airfoil cooling system. Flow guides may be positioned in the outer cooling channel, which may reduce cross-flow by the impingement orifices, thereby increasing effectiveness.
    Type: Grant
    Filed: November 8, 2013
    Date of Patent: September 6, 2016
    Assignee: Siemens Energy, Inc.
    Inventors: Carmen Andrew Scribner, Stephen John Messmann, Jan H. Marsh
  • Publication number: 20160177723
    Abstract: A turbine airfoil assembly for installation in a gas turbine engine. The airfoil assembly includes an endwall and an airfoil extending radially outwardly from the endwall. The airfoil includes pressure and suction sidewalls defining chordally spaced apart leading and trailing edges of the airfoil. An airfoil mean line is defined located centrally between the pressure and suction sidewalls. An angle between the mean line and a line parallel to the engine axis at the leading and trailing edges defines gas flow entry angles, ?, and exit angles, ?. Airfoil inlet and exit angles are substantially in accordance with inlet angle values, ?, and exit angle values, ?, set forth in one of Tables 1, 2, 3, and 4.
    Type: Application
    Filed: November 24, 2015
    Publication date: June 23, 2016
    Inventors: Andrew S. Lohaus, Anthony J. Malandra, Carmen Andrew Scribner, Farzad Taremi, Horia Flitan, Ching-Pang Lee, Gm Salam Azad, Tobias Buchal
  • Publication number: 20160096836
    Abstract: The present invention is directed to spirocyclic compounds which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPH1), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.
    Type: Application
    Filed: September 1, 2015
    Publication date: April 7, 2016
    Inventors: Stéphane De Lombaert, Daniel R. Goldberg, Kenneth Brameld, Eric Brian Sjogren, Andrew Scribner